FDA approves Newron's drug as add-on therapy for Parkinson's

(Reuters) - Newron Pharmaceuticals SpA said on Tuesday the U.S. Food and Drug Administration approved its Parkinson's disease treatment Xadago as an add-on therapy to levodopa, a drug widely used to treat the disease.